| Drug Name |
Vismodegib |
| Drug ID |
BADD_D02365 |
| Description |
Vismodegib inhibits the hedgehog signalling pathway and is indicated for treatment of adult basal cell carcinoma. FDA approved on Jan 30, 2012. |
| Indications and Usage |
Vismodegib is used for treating locally advanced or metastatic basal cell carcinoma in patients whose carcinoma has recurred after surgery, and in patients who are not candidates for surgery or radiation. |
| Marketing Status |
approved; investigational |
| ATC Code |
L01XJ01 |
| DrugBank ID |
DB08828
|
| KEGG ID |
D09992
|
| MeSH ID |
C538724
|
| PubChem ID |
24776445
|
| TTD Drug ID |
D03EDQ
|
| NDC Product Code |
50242-140 |
| UNII |
25X868M3DS
|
| Synonyms |
HhAntag691 | NSC 747691 | NSC747691 | NSC-747691 | R 3616 | R3616 cpd | R-3616 | vismodegib | erivedge | GDC 0449 | GDC0449 | GDC-0449 | RG 3616 | RG3616 | RG-3616 |
